Susceptibility of Candida species and various moulds to antimycotic drugs: Use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey

Medical Mycology

Volumn 49, Issue 8, 2011, Pages 856-863

  Rambach, Gnter ^a   Oberhauser, Heidemarie ^b   Speth, Cornelia ^a   Lass Flörl, Cornelia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Fhg University of Applied Sciences Tyrol   (Austria)

Author keywords

Antimycotic agents; Candida species; Epidemiological cutoff values; Moulds; Susceptibility resistance

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; AUSTRIA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; EPSILOMETER TEST; FUNGAL DETECTION; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; ZYGOMYCETES;

ANTIFUNGAL AGENTS; ASPERGILLUS; AUSTRIA; CANDIDA; DRUG RESISTANCE, FUNGAL; FUNGI; GUIDELINES AS TOPIC; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES;

ASPERGILLUS; CANDIDA; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; FUNGI; ZYGOMYCETES;

EID: 80054703661     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2011.583943     Document Type: Article

References (34)

1. Malani A, Kauffman C. Changing epidemiology of rare mould infections: implications for therapy. Drugs 2007; 67: 1803-1812. (Pubitemid 47347394)
2. Pfaller M, Pappas P, Wingard J. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006; 43: 3-14.
3. Pfaller M, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163. (Pubitemid 46167771)
4. Maschmeyer G, Calandra T, Singh N, Wiley J, Perfect J. Invasive mould infections: a multi-disciplinary update. Med Mycol 2009; 47: 571-583.
5. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005; 56: 5-11.
6. Fera MT, La CE, De SA. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther 2009; 7: 981-998.
7. Peman J, Canton E, Espinel-Ingroff A. Antifungal drug resistance mechanisms. Expert Rev Anti Infect Ther 2009; 7: 453-460.
8. Messer SA, Diekema DJ, Hollis RJ, et al. Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of f lamentous fungi. J Clin Microbiol 2007; 45: 1322-1324. (Pubitemid 46626507)
9. Pfaller M, Castanheira M, Diekema D, et al. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echino-candin susceptibility testing of Candida species. J Clin Microbiol 2010; 48: 1592-1599.
10. Turnidge J, Kahlmeter G, Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 2006; 12: 418-425.
11. Pfaller M, Boyken L, Hollis R, et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin. J Clin Microbiol 2011; 49: 624-629.
12. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 2009; 53: 112-122.
13. Arendrup M, Kahlmeter G, Rodriguez-Tudela JL, Donnelly JP. Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. Antimicrob Agents Chemother 2009; 53: 1628-1629.
14. Rodriguez-Tudela J, Arendrup M, Cuenca-Estrella M, Donnelly J, Lass-Florl C. EUCAST breakpoints for antifungals. Drug News Per-spect 2010; 23: 93-97.
15. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to f uconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366-1377.
16. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47: 3149-3154. (Pubitemid 37229571)
17. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posacon-azole, f uconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-2015. (Pubitemid 43807519)
18. Jung SI, Shin JH, Song JH, et al. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. Med Mycol 2010; 48: 669-674.
19. Diekema DJ, Messer SA, Boyken LB, et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol 2009; 47: 3170-3177.
20. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150-156.
21. Pfaller MA, Diekema DJ, Gibbs DL, et al. Geographic variation in the frequency of isolation and f uconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010; 67: 162-171.
22. Guinea J, Sanchez-Somolinos M, Cuevas O, Pelaez T, Bouza E. Fluconazole resistance mechanisms in Candida krusei: the contribution of eff ux-pumps. Med Mycol 2006; 44: 575-578. (Pubitemid 44377568)
23. Marr KA. Invasive Candida infections: the changing epidemiology. Oncology (Williston Park) 2004; 18: 9-14.
24. Lass-Flörl C, Griff K, Mayr A, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131: 201-207. (Pubitemid 43899686)
25. Richardson C, Lass-Florl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008; 14 (Suppl. 4): 5-24. (Pubitemid 351593913)
26. Hachem R, Kontoyiannis D, Boktour M, et al. Aspergillus terreus an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 2004; 101: 1594-1600. (Pubitemid 39318906)
27. Lass-Flörl C, Grif K, Kontoyiannis DP. Molecular typing of Aspergillus terreus isolates in Houston, Texas, and Innsbruck, Austria: evidence of great genetic diversity. J Clin Microbiol. 2007, 45; 2686-2690. (Pubitemid 47295505)
28. Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspo-fungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods. Diagn Microbiol Infect Dis 2010; 67: 56-60.
29. Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. Plos Med 2008; 5: e219.
30. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-1076.
31. Krishnan S, Manavathu EK, Chandrasekar PH. Aspergillus f avus: an emerging non-fumigatus Aspergillus species of signif cance. Mycoses 2009; 52: 206-222.
32. Alastruey-Izquierdo A, Castelli M V, Cuesta I, et al. In vitro activity of antifungals against Zygomycetes. Clin Microbiol Infect 2009; 15 (Suppl. 5): 71-76.
33. Cornely OA, Vehreschild JJ, Ruping MJ. Current experience in treating invasive zygomycosis with posaconazole. Clin Microbiol Infect 2009; 15 (Suppl. 5): 77-81.
34. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007; 51: 2587-2590. (Pubitemid 47047341)